Neuroprotective Mechanisms of the ACE2–Angiotensin-(1-7)–Mas Axis in Stroke

详细信息    查看全文

• 作者：Douglas M. Bennion ; Emily Haltigan ; Robert W. Regenhardt…
• 关键词：Angiotensin converting enzyme 2 ; Angiotensin ; (1 ; 7) ; Mas ; Angiotensin type 1 receptor ; Angiotensin type 2 receptor ; Renin ; angiotensin system ; Stroke ; Neuroprotection ; Neuron ; Microglia ; Ischemia ; Intracerebral hemorrhage ; Inflammation
• 刊名：Current Hypertension Reports
• 出版年：2015
• 出版时间：February 2015
• 年：2015
• 卷：17
• 期：2
• 全文大小：1,164 KB
• 参考文献：1. Dai W, Funk A, Herdegen T, Unger T, Culman J. Blockade of central angiotensin AT(1) receptors improves neurological outcome and reduces expression of AP-1 transcription factors after focal brain ischemia in rats. Stroke. 1999;30(11):2391-.
  2. Mecca AP, O'Connor TE, Katovich MJ, Sumners C. Candesartan pretreatment is cerebroprotective in a rat model of endothelin-1-induced middle cerebral artery occlusion. Exp Physiol. 2009;94(8):937-6. doi:10.1113/expphysiol.2009.047936 .
  3. Ong HT, Ong LM, Ho JJ. Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-receptor blockers (ARBs) in patients at high risk of cardiovascular events: a meta-analysis of 10 randomised placebo-controlled trials. ISRN Cardiol. 2013;2013:478597. doi:10.1155/2013/478597 .
  4. Joseph JP, Mecca AP, Regenhardt RW, Bennion DM, Rodriguez V, Desland F, et al. The angiotensin type 2 receptor agonist Compound 21 elicits cerebroprotection in endothelin-1 induced ischemic stroke. Neuropharmacology. 2014;81C:134-1. doi:10.1016/j.neuropharm.2014.01.044 .
  5. Min LJ, Mogi M, Tsukuda K, Jing F, Ohshima K, Nakaoka H, et al. Direct stimulation of angiotensin II type 2 receptor initiated after stroke ameliorates ischemic brain damage. Am J Hypertens. 2014;63(3):e 53-.
  6. McCarthy CA, Vinh A, Miller AA, Hallberg A, Alterman M, Callaway JK, et al. Direct angiotensin AT2 receptor stimulation using a novel AT2 receptor agonist, compound 21, evokes neuroprotection in conscious hypertensive rats. PLoS One. 2014;9(4):e95762. doi:10.1371/journal.pone.0095762 .
  7. Lee S, Brait VH, Arumugam TV, Evans MA, Kim HA, Widdop RE, et al. Neuroprotective effect of an angiotensin receptor type 2 agonist following cerebral ischemia in vitro and in vivo. Exp Transl Stroke Med. 2012;4(1):16. doi:10.1186/2040-7378-4-16 .
  8. McCarthy CA, Vinh A, Broughton BR, Sobey CG, Callaway JK, Widdop RE. Angiotensin II type 2 receptor stimulation initiated after stroke causes neuroprotection in conscious rats. Hypertension. 2012;60(6):1531-. doi:10.1161/HYPERTENSIONAHA.112.199646 . / This was the first demonstration of protective AT2R effects by pharmacological activation after the 18 onset of ischemic stroke in conscious rats, providing especially important information about the clinical potential of AT2R agonism in stroke.
  9. Gelosa P, Pignieri A, Fandriks L, de Gasparo M, Hallberg A, Banfi C, et al. Stimulation of AT2 receptor exerts beneficial effects in stroke-prone rats: focus on renal damage. J Hypertens. 2009;27(12):2444-1. doi:10.1097/HJH.0b013e3283311ba1 .
  10. Smith Jr SC. Reducing the global burden of ischemic heart disease and stroke: a challenge for the cardiovascular community and the United Nations. Circulation. 2011;124(3):278-. doi:10.1161/CIRCULATIONAHA.111.040170; 10.1161/CIRCULATIONAHA.111.040170 .
  11. Jauch EC, Saver JL, Adams Jr HP, Bruno A, Connors JJ, Demaerschalk BM, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44(3):870-47. doi:10.1161/STR.0b013e318284056a .
  12. Ginsberg MD. Neuroprotection for ischemic stroke: past, present and future. Neuropharmacology. 2008;55(3):363-9. doi:10.1016/j.neuropharm.2007.12.007 .
  13. Greenberg DA. Preclinical stroke research: gains and gaps. Stroke. 2013;44(6 Suppl 1):S114-. doi:10.1161/STROKEAHA.113.002088 .
  14. Lu J, Jiang T, Wu L, Gao L, Wang Y, Zhou F, et al. The expression of angiotensin-converting enzyme 2-angiotensin-(1-)-Mas receptor axis are upregulated after acute cerebral ischemic stroke in rats. Neuropeptides. 2013. doi:10.1016/j.npep.2013.09.002 .
  15. Fisher M. Characterizing the target of acute stroke therapy. Stroke. 1997;28(4):866-2.
  16. Pena Silva RA, Heistad DD. Promising neuroprotective effects of the angiotensin-(1-)-angiotensin-converting enzyme 2-Mas axis in stroke. Exp Physiol. 2014;99(2):342-. doi:10.1113/expphysiol.2013.076836 .
  17. Regenhardt RW, Bennion DM, Sumners C. Cerebroprotective action of angiotensin peptides in stroke. Clin Sci (Lond). 2014;126(3):195-05. doi:10.1042/CS20130324 .
  18. Kagiyama T, Kagiyama S, Phillips MI. Expression of angiotensin type 1 and 2 receptors in brain after transient middle cerebral artery occlusion in rats. Regul Pept. 2003;110(3):241-.
  19. Chang AY, Li FC, Huang CW, Wu JC, Dai KY,
• 作者单位：Douglas M. Bennion (1)
  Emily Haltigan (1)
  Robert W. Regenhardt (1)
  U. Muscha Steckelings (2)
  Colin Sumners (1)
  
  1. Department of Physiology and Functional Genomics & McKnight Brain Institute, University of Florida, 1600 SW Archer Road, PO Box 100274, Gainesville, FL, 32610-0274, USA
  2. Department of Cardiovascular and Renal Research, University of Southern Denmark, J.B. Winsl?ws Vej 21 3, 5000, Odense C, Denmark
  
• 刊物主题：Internal Medicine; Cardiology; Metabolic Diseases; Nephrology; Primary Care Medicine; General Practice / Family Medicine;
• 出版者：Springer US
• ISSN：1534-3111

文摘

The discovery of beneficial neuroprotective effects of the angiotensin converting enzyme 2–angiotensin-(1-7)–Mas axis [ACE2–Ang-(1-7)–Mas] in ischemic and hemorrhagic stroke has spurred interest in a more complete characterization of its mechanisms of action. Here, we summarize findings that describe the protective role of the ACE2–Ang-(1-7)–Mas axis in stroke, along with a focused discussion on the potential mechanisms of neuroprotective effects of Ang-(1-7) in stroke. The latter incorporates evidence describing the actions of Ang-(1-7) to counter the deleterious effects of angiotensin II (AngII) via its type 1 receptor, including anti-inflammatory, anti-oxidant, vasodilatory, and angiogenic effects, and the role of altered kinase–phosphatase signaling. Interactions of Mas with other receptors, including bradykinin receptors and AngII type 2 receptors are also considered. A more complete understanding of the mechanisms of action of Ang-(1-7) to elicit neuroprotection will serve as an essential step toward research into potential targeted therapeutics in the clinical setting.